Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Optimal, Off-the-Shelf, CAR-iNKT Cell Platform-Based Immunotherapy for Multiple Myeloma

Kanagaraju Ponnusamy, Lyra Randzavola, Hongwei Ren, Klesti Karaxhuku, Bryan Lye, Dimitrios Leonardos, Reza Nadafi, Irene Sarkar, Ilia Leontari, Farah Sabrin, Mehmood Zaidi, Marco Bua, Maria Atta, Alexia Katsarou, Irene Roberts, Aristeidis Chaidos, Anastasios Karadimitris

Blood (2023) 142 (Supplement 1): 3459.

https://doi.org/10.1182/blood-2023-189905

Published: 2023

Journal Articles

Immune Graft Composition Is Important for Deepening Response and Outcome after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma Who Do Not Receive Maintenance Therapy

Yeasung Lee, Francesca Bladt, Dimitrios Leonardos, Chira Mustafa, Alexia Katsarou, Maria Atta, Marco Bua, Ian Gabriel, Jose Ros-Soto, Alexandra Bazeos, Jiri Pavlu, Sandra Loaiza, Emma Bray, Farah O'Boyle, Elisabet Nadal, Richard Szydlo, Nicholas Crump, Anastasios Karadimitris, Aristeidis Chaidos

Blood (2023) 142 (Supplement 1): 759.

https://doi.org/10.1182/blood-2023-188912

Published: 2023

Journal Articles

Development of Novel Invariant TCR-Anchored Bispecific Engagers to Enhance Anti-Cancer Activity of iNKT Cells

Klesti Karaxhuku, Kanagaraju Ponnusamy, Hongwei Ren, Bryan Lye, Ilia Leontari, Mehmood Zaidi, Farah Sabrin, Marco Bua, Maria Atta, Alexia Katsarou, Irene Roberts, Aristeidis Chaidos, Anastasios Karadimitris

Blood (2023) 142 (Supplement 1): 4828.

https://doi.org/10.1182/blood-2023-190598

Published: 2023

Journal Articles

Distinct Chromatin Accessibility Changes, Aberrant Transcription Factor Networks Combined with Novel Oncogenic Enhancers Characterise Myeloma-Initiating Genetic Events

Nikolaos Trasanidis, Jaime Alvarez-Benayas, Alexia Katsarou, Aristeidis Chaidos, Philippa C May, Kanagaraju Ponnusamy, Xiaolin Xiao, Marco Bua, MD, Maria Atta, MD, Irene Roberts, Holger W Auner, MD PhD, Evdoxia Hatjiharissi, Maria Papaioannou, Valentina S Caputo, Ian Sudbery, Anastasios Karadimitris

Blood (2019) 134 (Supplement_1): 1769.

https://doi.org/10.1182/blood-2019-124761

Published: 2019

Journal Articles

Clustering Analysis of Myeloma Clone Phenotype Is Informative for Disease Heterogeneity and Prognosis at Relapse

Syeda Maheen Ahsan, Elisabet Nadal-Melsio, MD, Mark E Robinson, PhD, Richard Syzdlo, PhD, Eva Yebra-Fernandez, MD, Holger W Auner, MD PhD, Maria Atta, MD, Marco Bua, MD, Farah O'Boyle, PhD, Kikkeri Naresh, Jane Apperley, MB ChB MD, Anastasios Karadimitris, FRCPath, PhD, Aristeidis Chaidos, MD PhD

Blood (2018) 132 (Supplement 1): 4492.

https://doi.org/10.1182/blood-2018-99-117460

Published: 2018

Journal Articles

Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies

Pratap Neelakantan, Gareth Gerrard, Claire Lucas, Dragana Milojkovic, Philippa May, Lihui Wang, Christos Paliompeis, Marco Bua, Alistair Reid, Katayoun Rezvani, Stephen O'Brien, Richard Clark, John Goldman, David Marin

Blood (2013) 121 (14): 2739–2742.

https://doi.org/10.1182/blood-2012-11-466037

Published: 2013

Includes: Supplemental data

Journal Articles

Third Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma

Catherine Garnett, Chrissy Giles, Maialen Lasa, Osman Ahmed, Marco Bua, Holger W. Auner, Donald MacDonald, Sasha Marks, David Marin, Dragana Milojkovic, Jiri Pavlu, Saad Abdalla, Edward J Kanfer, Jane Apperley, Amin Rahemtulla

Blood (2012) 120 (21): 4548.

https://doi.org/10.1182/blood.V120.21.4548.4548

Published: 2012

Journal Articles

Tandem Autologous Stem Cell Transplantation in Chemorefractory Multiple Myeloma

Catherine Garnett, Chrissy Giles, Osman Ahmed, Maialen Lasa, Holger W. Auner, Donald MacDonald, Sasha Marks, David Marin, Dragana Milojkovic, Jiri Pavlu, Marco Bua, Saad Abdalla, Edward J Kanfer, Jane Apperley, Amin Rahemtulla

Blood (2012) 120 (21): 4554.

https://doi.org/10.1182/blood.V120.21.4554.4554

Published: 2012

Journal Articles

Is Major Molecular Response a Safe Haven Against Blast Crisis in Cml Patients Treated with Imatinib?

Pratap Neelakantan, MRCP, Dragana Milojkovic, Gareth Gerrard, PhD, Letizia Foroni, Jane Apperley, Richard M Szydlo, Alistair Reid, PhD, Marco Bua, Katy Rezvani, MBBS, PhD, MRCP, FRCPath, John M Goldman, MD, David Marin

Blood (2012) 120 (21): 3760.

https://doi.org/10.1182/blood.V120.21.3760.3760

Published: 2012

Journal Articles

Can the Combination of the Measurement of BCR-ABL1 Transcript Levels At 3 and 6 Months Improve the Prognostic Value of the 3 Month Measurement?

Pratap Neelakantan, MRCP, Gareth Gerrard, PhD, Letizia Foroni, Dragana Milojkovic, Jane Apperley, Richard Szydlo, PhD, Marco Bua, Alistair G Reid, BSc, PhD, Katy Rezvani, MBBS, PhD, MRCP, FRCPath, John M Goldman, MD, David Marin

Blood (2012) 120 (21): 68.

https://doi.org/10.1182/blood.V120.21.68.68

Published: 2012

Journal Articles

Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients

Dragana Milojkovic, Jane F. Apperley, Gareth Gerrard, Amr R. Ibrahim, Richard Szydlo, Marco Bua, Alistair Reid, Katayoun Rezvani, Letizia Foroni, John Goldman, David Marin

Blood (2012) 119 (8): 1838–1843.

https://doi.org/10.1182/blood-2011-10-383000

Published: 2012

Journal Articles

Assessment of BCR-ABL1 Transcript Levels At 3 Months Is the Only Requirement for Predicting Outcome for Patients with Chronic Myeloid Leukemia Treated with Imatinib

Dragana Milojkovic, MD, Amr R Ibrahim, Letizia Foroni, MD PhD, Claire Lucas, Gareth Gerrard, PhD, Lihui Wang, Richard M Szydlo, Richard E Clark, Jane F Apperley, MBChB, MD, FRCP, FRCPath, Marco Bua, MD, Jiri Pavlu, Christos Paliompeis, Alistair Reid, PhD, Katy Rezvani, MBBS, PhD, MRCP, FRCPath, John M Goldman, David Marin

Blood (2011) 118 (21): 1680.

https://doi.org/10.1182/blood.V118.21.1680.1680

Published: 2011

Journal Articles

The Natural History of RTQ-PCR Levels After the Achievement of Complete Molecular Remission (CMR): Implications for ‘Stopping' Studies

Dragana Milojkovic, MD, Gareth Gerrard, PhD, Christos Paliompeis, Marco Bua, MD, Alistair Reid, PhD, Mary Alikian, Jamshid Khorashad, MD, PhD, John M Goldman, David Marin, Letizia Foroni, MD PhD, Jane F Apperley, MBChB, MD, FRCP, FRCPath

Blood (2011) 118 (21): 605.

https://doi.org/10.1182/blood.V118.21.605.605

Published: 2011

Journal Articles

Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor Have Normal T Cell Responses to Vaccination but An Impaired IgM Humoral Response Associated with Loss of Discrete Memory B Cell Subsets,

Blood (2011) 118 (21): 3753.

https://doi.org/10.1182/blood.V118.21.3753.3753

Published: 2011

Journal Articles

Prolonged Survival Following Imatinib Failure for CML Patients in CP May Require Multiple TKI Strategies for Responding Patients,

Dragana Milojkovic, MD, Jane F Apperley, MBChB, MD, FRCP, FRCPath, Amr R Ibrahim, Marco Bua, MD, Alistair Reid, PhD, Gareth Gerrard, PhD, Letizia Foroni, MD PhD, Katy Rezvani, MBBS, PhD, MRCP, FRCPath, John M Goldman, David Marin

Blood (2011) 118 (21): 3777.

https://doi.org/10.1182/blood.V118.21.3777.3777

Published: 2011

Journal Articles

Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy

Amr R. Ibrahim, Lina Eliasson, Jane F. Apperley, Dragana Milojkovic, Marco Bua, Richard Szydlo, Francois-Xavier Mahon, Kasia Kozlowski, Christos Paliompeis, Letizia Foroni, Jamshid S. Khorashad, Alex Bazeos, Mathieu Molimard, Alistair Reid, Katayoun Rezvani, Gareth Gerrard, John Goldman, David Marin

Blood (2011) 117 (14): 3733–3736.

https://doi.org/10.1182/blood-2010-10-309807

Published: 2011

Journal Articles

Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy

Amr R. Ibrahim, Christos Paliompeis, Marco Bua, Dragana Milojkovic, Richard Szydlo, Jamshid S. Khorashad, Letizia Foroni, Alistair Reid, Hugues de Lavallade, Katayoun Rezvani, Francesco Dazzi, Jane F. Apperley, John M. Goldman, David Marin

Blood (2010) 116 (25): 5497–5500.

https://doi.org/10.1182/blood-2010-06-291922

Published: 2010

Journal Articles

KIR2DS1 Genotype Predicts for Cytogenetic Response, Progression-Free Survival and Overall Survival In Patients with Chronic Phase CML on Imatinib

Ian H Gabriel, MD, David Marin, MD, FRCP, Shahzad Ahmad, Mr, Letizia Foroni, Hugues de Lavallade, MD, Richard E. Clark, MBBS, MD, FRCP, FRCPath, Stephen O'Brien, PhD, Ruhena Sergeant, Dragana Milojkovic, MD, Marco Bua, Abdullah Alsuliman, Ahmad Khoder, Dr, Kate Stringaris, MD, MRCP, FRCPath, Nichola Cooper, MD, John M. Goldman, DM, FRCP, FRCPath, FMedSci, Jane F. Apperley, Katayoun Rezvani, MD, PhD

Blood (2010) 116 (21): 888.

https://doi.org/10.1182/blood.V116.21.888.888

Published: 2010

Journal Articles

Poor Adherence Is the Main Reason for Loss of CCyR and Imatinib Failure for CML Patients On Long Term Imatinib Therapy.

Amr R Ibrahim, Dragana Milojkovic, Marco Bua, Jamshid S Khorshad, Richard Szydlo, Lina Eliasson, Letizia Foroni, MD, PhD, Alistair Reid, Hugues de Lavallade, Katayoun Rezvani, MD, PhD, John M. Goldman, DM, FRCP, FRCPath, FMedSci, Jane Apperley, MBChB, FRCP, FRCPath, David Marin, MD, FRCP

Blood (2010) 116 (21): 3414.

https://doi.org/10.1182/blood.V116.21.3414.3414

Published: 2010

Journal Articles

Efficacy of Tyrosine Kinase Inhibitors (TKIs) as Third Line Therapy In Patients with Chronic Myeloid Leukaemia In Chronic Phase Who Have Failed Two Prior TKIs

Amr R Ibrahim, Marco Bua, Jamshid S Khorshad, Dragana Milojkovic, Lina Eliasson, Richard Szydlo, Letizia Foroni, MD, PhD, Alistair Reid, Hugues de Lavallade, Katayoun Rezvani, MD, PhD, John M. Goldman, DM, FRCP, FRCPath, FMedSci, Jane Apperley, MBChB, FRCP, FRCPath, David Marin, MD, FRCP

Blood (2010) 116 (21): 2274.

https://doi.org/10.1182/blood.V116.21.2274.2274

Published: 2010

NARROW

Optimal, Off-the-Shelf, CAR-iNKT Cell Platform-Based Immunotherapy for Multiple Myeloma

Immune Graft Composition Is Important for Deepening Response and Outcome after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma Who Do Not Receive Maintenance Therapy

Development of Novel Invariant TCR-Anchored Bispecific Engagers to Enhance Anti-Cancer Activity of iNKT Cells

Distinct Chromatin Accessibility Changes, Aberrant Transcription Factor Networks Combined with Novel Oncogenic Enhancers Characterise Myeloma-Initiating Genetic Events

Clustering Analysis of Myeloma Clone Phenotype Is Informative for Disease Heterogeneity and Prognosis at Relapse

Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies

Third Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma

Tandem Autologous Stem Cell Transplantation in Chemorefractory Multiple Myeloma

Is Major Molecular Response a Safe Haven Against Blast Crisis in Cml Patients Treated with Imatinib?

Can the Combination of the Measurement of BCR-ABL1 Transcript Levels At 3 and 6 Months Improve the Prognostic Value of the 3 Month Measurement?

Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients

Assessment of BCR-ABL1 Transcript Levels At 3 Months Is the Only Requirement for Predicting Outcome for Patients with Chronic Myeloid Leukemia Treated with Imatinib

The Natural History of RTQ-PCR Levels After the Achievement of Complete Molecular Remission (CMR): Implications for ‘Stopping' Studies

Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor Have Normal T Cell Responses to Vaccination but An Impaired IgM Humoral Response Associated with Loss of Discrete Memory B Cell Subsets,

Prolonged Survival Following Imatinib Failure for CML Patients in CP May Require Multiple TKI Strategies for Responding Patients,

Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy

Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy

KIR2DS1 Genotype Predicts for Cytogenetic Response, Progression-Free Survival and Overall Survival In Patients with Chronic Phase CML on Imatinib

Poor Adherence Is the Main Reason for Loss of CCyR and Imatinib Failure for CML Patients On Long Term Imatinib Therapy.

Efficacy of Tyrosine Kinase Inhibitors (TKIs) as Third Line Therapy In Patients with Chronic Myeloid Leukaemia In Chronic Phase Who Have Failed Two Prior TKIs

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only